TELESIS BIO INC (TBIO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TBIO • US1920032000

3.23 USD
-0.76 (-19.05%)
At close: Sep 27, 2024
2.85 USD
-0.38 (-11.76%)
After Hours: 9/27/2024, 8:22:41 PM
Fundamental Rating

1

TBIO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. TBIO has a bad profitability rating. Also its financial health evaluation is rather negative. TBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year TBIO has reported negative net income.
  • TBIO had a negative operating cash flow in the past year.
  • In the past 5 years TBIO always reported negative net income.
  • In the past 5 years TBIO always reported negative operating cash flow.
TBIO Yearly Net Income VS EBIT VS OCF VS FCFTBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -98.37%, TBIO is doing worse than 92.98% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -521.49%, TBIO is doing worse than 91.23% of the companies in the same industry.
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROIC N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
TBIO Yearly ROA, ROE, ROICTBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • TBIO's Gross Margin of 47.88% is in line compared to the rest of the industry. TBIO outperforms 54.39% of its industry peers.
  • In the last couple of years the Gross Margin of TBIO has grown nicely.
  • TBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
TBIO Yearly Profit, Operating, Gross MarginsTBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TBIO has more shares outstanding than it did 1 year ago.
  • TBIO has a better debt/assets ratio than last year.
TBIO Yearly Shares OutstandingTBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
TBIO Yearly Total Debt VS Total AssetsTBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -6.48, we must say that TBIO is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TBIO (-6.48) is worse than 91.23% of its industry peers.
  • TBIO has a Debt/Equity ratio of 0.54. This is a neutral value indicating TBIO is somewhat dependend on debt financing.
  • TBIO has a worse Debt to Equity ratio (0.54) than 63.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -6.48
ROIC/WACCN/A
WACC14.42%
TBIO Yearly LT Debt VS Equity VS FCFTBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that TBIO should not have too much problems paying its short term obligations.
  • The Current ratio of TBIO (1.89) is worse than 61.40% of its industry peers.
  • TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
  • TBIO has a Quick ratio (1.72) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.72
TBIO Yearly Current Assets VS Current LiabilitesTBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • TBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1673.33%.
  • Looking at the last year, TBIO shows a very negative growth in Revenue. The Revenue has decreased by -43.65% in the last year.
  • The Revenue has been growing by 61.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%

3.2 Future

  • TBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.72% yearly.
  • The Revenue is expected to decrease by -40.92% on average over the next years. This is quite bad
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TBIO Yearly Revenue VS EstimatesTBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TBIO Yearly EPS VS EstimatesTBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TBIO. In the last year negative earnings were reported.
  • Also next year TBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBIO Price Earnings VS Forward Price EarningsTBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBIO Per share dataTBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • TBIO's earnings are expected to decrease with -29.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TELESIS BIO INC

NASDAQ:TBIO (9/27/2024, 8:22:41 PM)

After market: 2.85 -0.38 (-11.76%)

3.23

-0.76 (-19.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07
Earnings (Next)11-11
Inst Owners2.63%
Inst Owner Change0%
Ins Owners5195.21%
Ins Owner Change0%
Market Cap5.72M
Revenue(TTM)17.53M
Net Income(TTM)-51.87M
Analysts82.86
Price Target4.08 (26.32%)
Short Float %0.03%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.05%
Min EPS beat(2)-85.37%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-35.22%
Min EPS beat(4)-85.37%
Max EPS beat(4)-2.5%
EPS beat(8)4
Avg EPS beat(8)-9.5%
EPS beat(12)5
Avg EPS beat(12)-9.14%
EPS beat(16)8
Avg EPS beat(16)19.54%
Revenue beat(2)0
Avg Revenue beat(2)-63.87%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-51.12%
Revenue beat(4)0
Avg Revenue beat(4)-39.08%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)-2.28%
Revenue beat(8)2
Avg Revenue beat(8)-15.2%
Revenue beat(12)4
Avg Revenue beat(12)-9.56%
Revenue beat(16)5
Avg Revenue beat(16)-24.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-101.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 1
EV/EBITDA N/A
EPS(TTM)-23.94
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-12.84
FCFYN/A
OCF(TTM)-12.31
OCFYN/A
SpS9.9
BVpS5.62
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.88%
FCFM N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.13%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.72
Altman-Z -6.48
F-Score4
WACC14.42%
ROIC/WACCN/A
Cap/Depr(3y)185.64%
Cap/Depr(5y)117.94%
Cap/Sales(3y)13.42%
Cap/Sales(5y)9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A

TELESIS BIO INC / TBIO FAQ

Can you provide the ChartMill fundamental rating for TELESIS BIO INC?

ChartMill assigns a fundamental rating of 1 / 10 to TBIO.


What is the valuation status of TELESIS BIO INC (TBIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to TELESIS BIO INC (TBIO). This can be considered as Overvalued.


Can you provide the profitability details for TELESIS BIO INC?

TELESIS BIO INC (TBIO) has a profitability rating of 1 / 10.


What is the financial health of TELESIS BIO INC (TBIO) stock?

The financial health rating of TELESIS BIO INC (TBIO) is 2 / 10.


What is the expected EPS growth for TELESIS BIO INC (TBIO) stock?

The Earnings per Share (EPS) of TELESIS BIO INC (TBIO) is expected to decline by -122.26% in the next year.